Who Owns Tylenol?
Updated onExplore the ownership hierarchy of Tylenol. See parent companies, holding structures, and ultimate controllers.
Ownership Chain
Tylenol
Tylenol is an over-the-counter brand of acetaminophen-based pain reliever and fever reducer sold by consumer health company Kenvue.
Starts at $2 / 10-count travel pack
Kenvue
Kenvue is a publicly traded American consumer health company, spun off from Johnson & Johnson, that owns iconic over-the-counter and personal care brands such as Tylenol, Neutrogena, Band-Aid, and Listerine.
Tylenol
Tylenol is an over-the-counter brand of acetaminophen-based pain reliever and fever reducer sold by consumer health company Kenvue.
Starts at $2 / 10-count travel pack
Kenvue
Kenvue is a publicly traded American consumer health company, spun off from Johnson & Johnson, that owns iconic over-the-counter and personal care brands such as Tylenol, Neutrogena, Band-Aid, and Listerine.
Major Shareholders
Tylenol
Major Shareholders
| Name | Type | Ownership | As of |
|---|---|---|---|
The Vanguard Group, Inc. Largest institutional shareholder of Kenvue Inc. (NYSE: KVUE), which owns the Tylenol brand; holds roughly 233.3M KVUE shares (~12.18% of shares outstanding) based on major-holder disclosures. | Institutional | 12.2% | Sep 2025 |
BlackRock, Inc. Second‑largest disclosed holder of Kenvue, with about 144.8M KVUE shares (~7.56% of the company) according to institutional ownership filings. | Institutional | 7.6% | Sep 2025 |
T. Rowe Price Associates, Inc. Major active manager in Kenvue, reporting beneficial ownership of roughly 115.1M KVUE shares (~6.0% of outstanding common stock) in recent Schedule 13G/A and holder summaries. | Institutional | 6.0% | Sep 2025 |
State Street Corporation Large index and ETF provider holding approximately 114.8M KVUE shares (~5.99% of Kenvue) as one of the top institutional shareholders. | Institutional | 6.0% | Sep 2025 |
FMR LLC (Fidelity Investments) FMR LLC, parent of Fidelity, reported beneficial ownership of about 90.3M KVUE shares (~4.7% of the class) in its Schedule 13G/A, making it one of Kenvue’s five largest shareholders. | Institutional | 4.7% | Sep 2025 |
Kenvue
Major Shareholders
| Name | Type | Ownership | Voting | As of |
|---|---|---|---|---|
The Vanguard Group, Inc. Largest shareholder; holds KVUE primarily through index and ETF products. Based on institutional holder data and Schedule 13G/A filings as of mid‑2025. | Institutional | 12.2% | 12.2% | Sep 2025 |
BlackRock, Inc. Major passive asset manager; stake disclosed in institutional holder data and a Schedule 13G/A reporting ~6.7–7.6% beneficial ownership. | Institutional | 7.6% | 7.6% | Sep 2025 |
Price (T. Rowe) Associates Inc. Active asset manager (T. Rowe Price); multiple Schedule 13G filings show it as a >5% beneficial owner during 2024–2025. | Institutional | 6.0% | 6.0% | Sep 2025 |
State Street Corporation Large index and ETF provider; Schedule 13G filing in late 2024 reported about a 6.6% stake, with Q3 2025 institutional data showing just under 6%. | Institutional | 6.0% | 6.0% | Sep 2025 |
FMR LLC (Fidelity) Parent of Fidelity Investments; a Schedule 13G/A dated September 30, 2025 reports beneficial ownership of ~90.3M shares (~4.7% of Kenvue). | Institutional | 4.7% | 4.7% | Sep 2025 |
Get Started
Your ultimate competitive playbook
You just found your top competitors. Now let's map your whole landscape and show you how to stand out.
Competitive Landscape Report
Built for small teams who can't hire a full-time analyst.
$129 $260 one-time payment
Generated in minutes, no subscription.
Instead of guessing what to do about your competitors, get a done-for-you intelligence report
Competitor Map
Direct, indirect, and alternative competitors mapped across your market
Positioning Analysis
How each competitor positions, their ICP, and key differentiators
Feature & Pricing Matrix
Side-by-side comparison of features, pricing, and packaging strategies
Growth Channel Analysis
SEO, paid ads, content, and social strategies across the landscape
Reputation & Social Proof
Ratings, reviews, and sentiment analysis across all competitors
90-Day Action Plan
Specific tactics to differentiate and win more deals in the next 3 months